1110057K04Rik Inhibitors
Chemical inhibitors of 1110057K04Rik can intervene with its function by various modes of action, each specific to the inhibitor's target within the cell's signaling pathways. Staurosporine, a broad-spectrum kinase inhibitor, can obstruct several kinases that could be responsible for phosphorylating 1110057K04Rik, thereby impacting its activity. Similarly, Bisindolylmaleimide I, as a protein kinase C (PKC) inhibitor, can also impede the function of 1110057K04Rik if it is regulated by PKC-dependent signaling. LY294002 and Wortmannin, both phosphoinositide 3-kinases (PI3K) inhibitors, can disrupt PI3K-dependent pathways possibly associated with 1110057K04Rik's activity. The influence of these inhibitors underscores the pivotal role of kinase signaling in the regulation of 1110057K04Rik.
Furthermore, Rapamycin, by selectively inhibiting mTOR, can influence 1110057K04Rik's involvement in mTOR-dependent pathways. U0126 and PD98059, which target MEK1/2, can prevent the activation of ERK, potentially affecting 1110057K04Rik's function if it operates downstream of the MAPK/ERK pathway. SB203580, as a p38 MAP kinase inhibitor, can disrupt the p38 MAPK signaling pathway, which may be essential for the function of 1110057K04Rik. SP600125, which inhibits c-Jun N-terminal kinase (JNK), can prevent JNK-mediated signal transduction involving 1110057K04Rik. Dasatinib, with its broad-spectrum inhibition of tyrosine kinases, can block critical enzymes that could be involved in the activation or function of 1110057K04Rik. Finally, Lapatinib and PP2, by respectively targeting EGFR/HER2 and Src family tyrosine kinases, can affect the signaling events and pathways that regulate the function of 1110057K04Rik. Each inhibitor's action reflects the complexity of cell signaling and the multiple points at which 1110057K04Rik's function can be modulated.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a potent kinase inhibitor, can inhibit kinase-dependent signaling pathways where 1110057K04Rik may be involved. By blocking these kinases, Staurosporine would inhibit the phosphorylation on which 1110057K04Rik relies for its activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a selective inhibitor of protein kinase C (PKC). If 1110057K04Rik's function is mediated by PKC-dependent signaling, the inhibition of PKC would lead to a reduction in 1110057K04Rik activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 would disrupt PI3K-dependent pathways, potentially inhibiting processes that require 1110057K04Rik's activity, such as signal transduction events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin functions as a PI3K inhibitor. By specifically inhibiting PI3K, Wortmannin would impede any PI3K-mediated activities of 1110057K04Rik, such as those involved in cell growth and survival, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin). If 1110057K04Rik is involved in an mTOR-dependent pathway, the inhibition of mTOR would lead to a decrease in 1110057K04Rik's functional activity related to protein synthesis and cell cycle control. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators in the MAPK/ERK pathway. Inhibition of MEK1/2 by U0126 would block the activation of ERK, which may be necessary for 1110057K04Rik's activity, leading to its functional inhibition within this signaling context. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which would prevent ERK activation. If 1110057K04Rik functions downstream of the MAPK/ERK pathway, PD98059 would inhibit this pathway and consequently inhibit the activity of 1110057K04Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, SB203580 would disrupt the p38 MAPK signaling pathway, which could be essential for the function of 1110057K04Rik, thus functionally inhibiting it. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK by SP600125 could prevent signal transduction that is mediated by JNK pathway where 1110057K04Rik is functionally involved, thus inhibiting 1110057K04Rik activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. It would inhibit tyrosine kinases that are potentially involved in the activation or function of 1110057K04Rik, leading to the functional inhibition of this protein by blocking these signaling molecules. | ||||||